---
name: analyzing-anti-trust-risk
language: en
description: Evaluates competition law exposure with market definition, HHI analysis, and remedy estimation for proposed transactions. Use when assessing merger clearance risk, analyzing market concentration, or preparing HSR filings.
tags:
  - analysis
  - mergers-and-acquisitions
  - risk
metadata:
  author: casemark
  practice_areas:
    - M&A Advisory
    - Corporate Development
    - Investment Banking
  document_types:
    - Analysis Report
  skill_modes:
    - Analysis
---
# Analyzing Anti Trust Risk

Evaluates competition law exposure with market definition, HHI analysis, and remedy estimation for proposed transactions.

## When To Use

- Assessing merger or acquisition clearance risk before signing or announcement
- Preparing or reviewing HSR (Hart-Scott-Rodino) filing strategy and timing
- Evaluating whether a bolt-on acquisition triggers size-of-transaction or size-of-person thresholds [VERIFY: current HSR thresholds adjust annually]
- Analyzing market concentration impact for board presentations or investment committee memos
- Screening a target portfolio for divestitures likely required as merger remedies
- Supporting second-request preparation or response strategy

## Inputs To Gather

- **Transaction details**: deal structure (stock vs. asset), purchase price, combined entity post-close
- **Party financials**: total assets and annual net sales for both buyer and target (for HSR threshold analysis)
- **Relevant product/service markets**: descriptions of overlapping business lines, substitutes, and complements
- **Geographic scope**: national, regional, or local market definitions as applicable
- **Market share data**: revenue or unit-based shares for each party and top competitors in each relevant market
- **Customer and supplier concentration**: key accounts, switching costs, and contractual lock-in periods
- **Prior agency interactions**: any previous DOJ/FTC investigations, consent decrees, or clearance history involving either party
- **Comparable transactions**: recent deals in the same sector and their regulatory outcomes

## Workflow

1. **Determine HSR applicability**
   - Calculate size-of-transaction and size-of-person tests against current thresholds [VERIFY: thresholds update each February]
   - Identify whether any exemptions apply (e.g., acquisitions of non-voting securities, certain real estate transactions)
   - Flag if foreign antitrust filings are also required (EU merger regulation, CMA, SAMR, etc.) [VERIFY: jurisdiction-specific thresholds]

2. **Define relevant markets**
   - Identify candidate product markets using the hypothetical monopolist (SSNIP) framework
   - Delineate geographic markets based on customer purchasing patterns, transportation costs, and regulatory boundaries
   - Document alternative reasonable market definitions and note how each affects concentration metrics

3. **Calculate market concentration (HHI)**
   - Compute pre-merger HHI for each relevant market
   - Compute post-merger HHI and the delta (change in HHI)
   - Apply DOJ/FTC Horizontal Merger Guidelines thresholds:
     - Post-merger HHI < 1,500: unconcentrated — unlikely to raise concerns
     - Post-merger HHI 1,500–2,500: moderately concentrated — delta > 100 warrants scrutiny
     - Post-merger HHI > 2,500: highly concentrated — delta > 200 presumptively raises concerns [VERIFY: confirm current Guidelines thresholds]

4. **Assess competitive effects**
   - **Unilateral effects**: evaluate whether the merged firm could profitably raise prices due to elimination of close substitutes; assess diversion ratios where data permits
   - **Coordinated effects**: evaluate whether the merger increases likelihood of tacit coordination among remaining competitors (market transparency, product homogeneity, history of coordination)
   - **Vertical effects**: if the deal has a vertical dimension, assess foreclosure risk to rivals or customers
   - **Buyer power / countervailing factors**: consider whether large buyers or low barriers to entry offset concentration concerns

5. **Evaluate likely remedies and timing risk**
   - Identify product lines or geographies most likely to require divestiture
   - Estimate the value and operational feasibility of potential divestitures
   - Assess whether behavioral remedies (firewalls, licensing) might be accepted as alternatives
   - Project regulatory timeline: initial waiting period, likelihood of second request, estimated time to clearance or litigation

6. **Assign overall risk rating**
   - **Low**: unconcentrated markets, no significant overlap, clean filing expected
   - **Moderate**: moderately concentrated markets or delta in sensitive range; second request possible but clearance likely with limited remedies
   - **High**: highly concentrated markets with significant delta; second request expected; material divestitures or deal restructuring likely required
   - **Prohibitive**: agency challenge highly probable; litigation risk or deal abandonment should be modeled

## Output

The deliverable should include:

- **Executive summary**: one-paragraph risk assessment with overall rating (Low / Moderate / High / Prohibitive)
- **HSR filing analysis**: threshold calculations, filing fee estimate, and timing implications
- **Market-by-market concentration table**: relevant market, parties' shares, pre/post HHI, delta, and risk flag
- **Competitive effects narrative**: concise analysis of unilateral, coordinated, and vertical theories of harm
- **Remedy scenario matrix**: potential divestitures or conditions mapped to affected markets, with estimated impact on deal value
- **Timeline and process overview**: expected regulatory milestones from filing through clearance
- **Key assumptions and data gaps**: explicit list of inputs assumed or unavailable, each flagged with [VERIFY] where appropriate

## Quality Checks

- HHI calculations verified against stated market shares (shares should sum to approximately 100%)
- HSR threshold figures cross-referenced against the most recent annual adjustment [VERIFY]
- Market definitions are internally consistent — product and geographic boundaries align with the data used for share calculations
- Risk rating is consistent with the quantitative concentration analysis and qualitative competitive effects discussion
- Remedy estimates are grounded in precedent from comparable transactions, not speculative
- All jurisdiction-dependent figures, thresholds, and filing requirements are marked [VERIFY]
- Analysis distinguishes between confirmed data and estimates/assumptions throughout